Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 16 | 2026 | 475 | 7.960 |
Why?
|
| Antihypertensive Agents | 11 | 2026 | 157 | 4.750 |
Why?
|
| Blood Pressure | 9 | 2026 | 278 | 4.570 |
Why?
|
| Cardiovascular Diseases | 9 | 2026 | 520 | 3.440 |
Why?
|
| Atrial Fibrillation | 7 | 2026 | 173 | 3.430 |
Why?
|
| Anticoagulants | 5 | 2026 | 127 | 2.610 |
Why?
|
| Atherosclerosis | 5 | 2025 | 51 | 2.440 |
Why?
|
| Aged | 33 | 2026 | 5901 | 2.060 |
Why?
|
| Humans | 51 | 2026 | 16832 | 2.050 |
Why?
|
| Male | 39 | 2026 | 9556 | 1.990 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2026 | 515 | 1.950 |
Why?
|
| Retrospective Studies | 25 | 2026 | 2463 | 1.890 |
Why?
|
| Female | 38 | 2026 | 12193 | 1.820 |
Why?
|
| Adult | 28 | 2026 | 7255 | 1.800 |
Why?
|
| California | 16 | 2026 | 2244 | 1.760 |
Why?
|
| Middle Aged | 33 | 2026 | 7515 | 1.730 |
Why?
|
| Hemorrhage | 3 | 2026 | 62 | 1.570 |
Why?
|
| Diabetes Complications | 3 | 2021 | 93 | 1.560 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 17 | 1.540 |
Why?
|
| Medication Adherence | 6 | 2020 | 235 | 1.530 |
Why?
|
| Cholesterol, LDL | 3 | 2025 | 113 | 1.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2025 | 155 | 1.420 |
Why?
|
| Hypoglycemic Agents | 7 | 2025 | 247 | 1.370 |
Why?
|
| Stroke | 6 | 2023 | 297 | 1.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2025 | 677 | 1.300 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 189 | 1.300 |
Why?
|
| Young Adult | 13 | 2026 | 2456 | 1.260 |
Why?
|
| United States | 13 | 2026 | 3858 | 1.240 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 445 | 1.240 |
Why?
|
| Risk Factors | 14 | 2026 | 3108 | 1.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 80 | 1.170 |
Why?
|
| Kidney Diseases | 2 | 2026 | 51 | 1.120 |
Why?
|
| Risk Assessment | 10 | 2026 | 1047 | 1.110 |
Why?
|
| Warfarin | 3 | 2021 | 72 | 1.080 |
Why?
|
| Adolescent | 12 | 2026 | 3464 | 1.040 |
Why?
|
| Aged, 80 and over | 12 | 2026 | 1887 | 1.030 |
Why?
|
| Electronic Health Records | 2 | 2026 | 702 | 0.970 |
Why?
|
| Delayed Diagnosis | 1 | 2026 | 21 | 0.960 |
Why?
|
| Thrombosis | 1 | 2026 | 16 | 0.950 |
Why?
|
| Language | 1 | 2026 | 51 | 0.950 |
Why?
|
| Algorithms | 2 | 2026 | 210 | 0.940 |
Why?
|
| Office Visits | 1 | 2026 | 78 | 0.930 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2026 | 57 | 0.900 |
Why?
|
| Aspirin | 2 | 2015 | 61 | 0.880 |
Why?
|
| Treatment Outcome | 7 | 2026 | 1098 | 0.850 |
Why?
|
| Incidence | 6 | 2026 | 1229 | 0.830 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 213 | 0.810 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 290 | 0.800 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 51 | 0.790 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.780 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 7 | 0.770 |
Why?
|
| Time Factors | 5 | 2026 | 989 | 0.770 |
Why?
|
| Hyperkalemia | 1 | 2023 | 14 | 0.770 |
Why?
|
| Comorbidity | 8 | 2020 | 516 | 0.740 |
Why?
|
| Telemedicine | 1 | 2026 | 190 | 0.740 |
Why?
|
| Prevalence | 7 | 2022 | 785 | 0.700 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 24 | 0.690 |
Why?
|
| Drug Therapy, Combination | 4 | 2026 | 104 | 0.670 |
Why?
|
| Health Care Costs | 2 | 2020 | 192 | 0.660 |
Why?
|
| Health Expenditures | 2 | 2019 | 69 | 0.660 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 13 | 0.660 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 17 | 0.640 |
Why?
|
| Predictive Value of Tests | 3 | 2026 | 325 | 0.630 |
Why?
|
| Reproducibility of Results | 4 | 2026 | 346 | 0.580 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2026 | 353 | 0.580 |
Why?
|
| Hepatitis C | 1 | 2019 | 54 | 0.570 |
Why?
|
| Antiviral Agents | 1 | 2019 | 92 | 0.570 |
Why?
|
| Cost of Illness | 1 | 2018 | 90 | 0.540 |
Why?
|
| Societies, Medical | 1 | 2018 | 67 | 0.520 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 43 | 0.480 |
Why?
|
| Guideline Adherence | 1 | 2018 | 155 | 0.480 |
Why?
|
| Quality of Life | 1 | 2019 | 477 | 0.460 |
Why?
|
| Blood Coagulation | 1 | 2015 | 3 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 24 | 0.450 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 45 | 0.440 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 185 | 0.430 |
Why?
|
| Quality of Health Care | 1 | 2016 | 249 | 0.420 |
Why?
|
| Managed Care Programs | 1 | 2016 | 275 | 0.420 |
Why?
|
| Natural Language Processing | 1 | 2015 | 60 | 0.420 |
Why?
|
| Mass Screening | 2 | 2018 | 670 | 0.420 |
Why?
|
| Cost-Benefit Analysis | 2 | 2026 | 229 | 0.400 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2026 | 40 | 0.380 |
Why?
|
| Age Factors | 4 | 2025 | 814 | 0.380 |
Why?
|
| Administration, Oral | 3 | 2023 | 81 | 0.360 |
Why?
|
| Sex Factors | 2 | 2026 | 560 | 0.350 |
Why?
|
| Sensitivity and Specificity | 3 | 2026 | 291 | 0.350 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1204 | 0.310 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 215 | 0.300 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1058 | 0.300 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 1233 | 0.290 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2025 | 14 | 0.280 |
Why?
|
| Hospitalization | 3 | 2026 | 816 | 0.280 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 21 | 0.240 |
Why?
|
| Osteoarthritis | 2 | 2016 | 15 | 0.240 |
Why?
|
| Hemostasis | 1 | 2026 | 1 | 0.240 |
Why?
|
| Blood Pressure Determination | 1 | 2026 | 57 | 0.240 |
Why?
|
| Metapneumovirus | 1 | 2026 | 7 | 0.240 |
Why?
|
| Paramyxoviridae Infections | 1 | 2026 | 8 | 0.240 |
Why?
|
| Health Resources | 1 | 2026 | 35 | 0.230 |
Why?
|
| Hawaii | 1 | 2026 | 62 | 0.230 |
Why?
|
| Respiratory Tract Infections | 1 | 2026 | 58 | 0.230 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 489 | 0.220 |
Why?
|
| Case-Control Studies | 2 | 2019 | 995 | 0.220 |
Why?
|
| Prognosis | 1 | 2026 | 568 | 0.220 |
Why?
|
| Logistic Models | 2 | 2019 | 796 | 0.210 |
Why?
|
| Proteinuria | 1 | 2024 | 24 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 653 | 0.200 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.200 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.200 |
Why?
|
| Pyridones | 1 | 2023 | 9 | 0.200 |
Why?
|
| Aldosterone | 1 | 2023 | 2 | 0.200 |
Why?
|
| Potassium | 1 | 2023 | 14 | 0.190 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 16 | 0.190 |
Why?
|
| Creatinine | 1 | 2023 | 67 | 0.190 |
Why?
|
| Dementia | 1 | 2025 | 137 | 0.190 |
Why?
|
| Diuretics | 1 | 2022 | 17 | 0.190 |
Why?
|
| Spironolactone | 1 | 2021 | 7 | 0.180 |
Why?
|
| Angioedema | 1 | 2021 | 5 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 11 | 0.170 |
Why?
|
| Bioprosthesis | 1 | 2021 | 1 | 0.170 |
Why?
|
| Heart Valves | 1 | 2021 | 2 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 14 | 0.170 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.160 |
Why?
|
| Drug Combinations | 1 | 2020 | 42 | 0.160 |
Why?
|
| Recurrence | 1 | 2020 | 149 | 0.160 |
Why?
|
| Coinfection | 1 | 2020 | 28 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 114 | 0.160 |
Why?
|
| Social Class | 1 | 2020 | 106 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2025 | 2396 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 374 | 0.150 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 400 | 0.140 |
Why?
|
| Drug Monitoring | 2 | 2017 | 23 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2008 | 36 | 0.140 |
Why?
|
| Ethnic Groups | 1 | 2020 | 418 | 0.130 |
Why?
|
| Canada | 1 | 2017 | 74 | 0.130 |
Why?
|
| Testosterone | 1 | 2017 | 19 | 0.130 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 27 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2020 | 292 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 382 | 0.120 |
Why?
|
| Heart Failure | 1 | 2021 | 403 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 2 | 2025 | 30 | 0.110 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 17 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 657 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 358 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 10 | 0.100 |
Why?
|
| Causality | 1 | 2013 | 32 | 0.100 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2026 | 29 | 0.100 |
Why?
|
| Budgets | 1 | 2011 | 5 | 0.090 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 22 | 0.080 |
Why?
|
| Cost Sharing | 1 | 2010 | 28 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 196 | 0.070 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 1 | 0.070 |
Why?
|
| Remission Induction | 1 | 2025 | 22 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 553 | 0.060 |
Why?
|
| Length of Stay | 1 | 2026 | 169 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 60 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2026 | 102 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2023 | 184 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 41 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 114 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 289 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 12 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 20 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2017 | 4 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 54 | 0.030 |
Why?
|
| Models, Economic | 1 | 2011 | 16 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 78 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 66 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 64 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 84 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 48 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 78 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 3 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 7 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 4 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 69 | 0.020 |
Why?
|
| Brain | 1 | 2008 | 47 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 261 | 0.020 |
Why?
|
Concepts
(181)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->